LOGIN  |  REGISTER
Recursion

Natera to Report its Second Quarter 2024 Results on August 8, 2024

July 30, 2024 | Last Trade: US$124.16 2.57 -2.03

AUSTIN, Texas / Jul 30, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).

Earnings Conference Call Information:

Event:

Natera’s Second Quarter 2024 Financial Results

Date:

Thursday, Aug. 8, 2024

Time:

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In:

 

1-888-596-4144 (Domestic)
1-646-968-2525 (International)

Conference ID:

7684785

Webcast:

https://events.q4inc.com/attendee/455235752

A webcast replay will be available at investor.natera.com.

About Natera

Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 200 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB